

h
26
B4

196. (Amended) The method of claim 187, wherein the second agent is selected from the group consisting of analeptic, analgesic, anesthetic, adrenergic agent, anti-adrenergic agent, adrenocortical steroid, amino acids, antagonists, antidote, anti-anxiety agent, anticholinergic, anticoagulant, anticolvunsant, antidepressant, anti-emetic, anti-epileptic, antihypertensive, antifibrinolytic, antihyperlipidemic, anti-inflammatory, antimigraine, antinauseant, antineoplastic (brain cancer), antiobessional agent, antiparkinsonian, antiproliferative, antipsychotic, antithrombotic, appetite suppressant, blood glucose regulator, cognition adjuvant, cognition enhancer, cholinergic agonist, dopaminergic agent, emetic, estrogen, fibrinolytic, free oxygen radical scavenger, glucocorticoid, hypocholesterolemic, hollylipidemic, histamine H2 receptor antagonists, immunosuppressant, inhibitor, memory adjuvant, mental performance enhancer, mood regulator, mydriatic, neuromuscular blocking agent, neuroprotective, NMDA antagonist, plasminogen activator, post-stroke and post-head trauma treatment, psychotropic, sedative, sedative-hypnotic, serotonin inhibitor, steroid, tranquilizer, and treatment of cerebral ischemia, calcium channel blockers, free radical scavengers – antioxidants, GABA agonists, glutamate antagonists, AMPA antagonists, kainate antagonists, competitive and non-competitive NMDA antagonists, growth factors, opioid antagonists, phosphatidylcholine precursors, serotonin agonists, sodium- and calcium-channel blockers, and potassium channel openers.

B5

199. (Amended) The method of claim [197] 192, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

B6

203. (Amended) The method of claim [201] 193, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

B7

215. (Amended) The method of claim [213] 182, further comprising co-administering an endothelial cell Nitric Oxide Synthase cofactor.

Please add the following new claims 217-223:

B8

217. The method of claim 168, wherein blood flow is increased in a subject with a neurodegenerative disease.

218. The method of claim 217, wherein the neurodegenerative disease is Alzheimer's disease.